GlassScriptPhysician profile
Nancy Supan Jacob
NPI 1740019231
$4,952.48
in general payments reported to CMS, 2019-2025
20 companies · $2,898 in 2025
The $2,898 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.13 · 2023: $125 · 2024: $1,831 · 2025: $2,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,106.15 | 2023-2025 | Airsupra, Farxiga, Tezspire |
| Lilly USA, LLC | $494.11 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $443.36 | 2024-2025 | Krystexxa, Repatha |
| Abbvie INC. | $432.43 | 2024-2025 | |
| Novo Nordisk INC | $386.41 | 2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $334.41 | 2024-2025 | Arexvy |
| Corcept Therapeutics | $250.00 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $249.13 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $233.41 | 2024-2025 | Rexulti |
| Heartflow, INC. | $150.00 | 2025 | |
| Recordati_rare_diseases_inc. | $132.89 | 2025 | Isturisa |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $112.95 | 2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $109.96 | 2025 | Camzyos |
| Organogenesis INC. | $104.01 | 2024 | Puraply Wound Matrix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.08 | 2025 | |
| Aurinia Pharma U.S., INC. | $71.98 | 2024 | Lupkynis |
| Phathom Pharmaceuticals, INC. | $71.52 | 2025 | Voquezna |
| Calliditas Therapeutics US INC. | $26.25 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $15.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.